Skip to main content
SpringerLink
Log in

Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Advanced glycation end-products (AGEs) are formed by spontaneous chemical reactions between carbohydrates and tissue proteins. The accumulation of AGEs in long-lived proteins contributes to the age-related increase in brown colour, fluorescence and insolubilisation of lens crystallins and to the gradual crosslinking and decrease in elasticity of connective tissue collagens with age. These nonenzymatic reactions, known collectively as Maillard or browning reactions, are also implicated in the development of pathophysiology in age-related diseases such as diabetes mellitus, atherosclerosis, Alzheimer’s disease, and in dialysis-related amyloidosis. Oxygen and oxidation reactions accelerates Maillard reactions in vitro, and the structurally characterised AGEs that accumulate in long-lived tissue proteins are in fact glycoxidation products, formed by sequential glycation and oxidation reactions.

In addition to their immediate effects on protein structure and function, AGEs also induce oxidative stress, leading to inflammation and propagation of tissue damage. Thus, glycation of protein, formation of AGEs and resultant oxidative stress, which accelerate Maillard reactions, can initiate an autocatalytic cycle of deleterious reactions in tissues.

Pharmacological inhibition of the Maillard reaction should improve the prognosis for a broad range of age-related diseases. The role of oxidative stress as a catalyst and the consequences of Maillard reaction damage in tissues suggests that antioxidant therapy may also retard the progression of age-related pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Hebd Seances Acad Sci 1912; 154: 66–8

    CAS  Google Scholar 

  2. Cohen MP. Diabetes and protein glycosylation: measurement and biological relevance. New York: Springer-Verlag, 1986

    Book  Google Scholar 

  3. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1–34

    Article  PubMed  CAS  Google Scholar 

  4. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994; 124: 19–30

    PubMed  CAS  Google Scholar 

  5. Baynes JW, Watkins NG, Fisher CI, et al. The Amadori product on protein. In: Baynes JW, Monnier VM, editors. The Maillard reaction in aging, diabetes, and nutrition. New York: Alan R. Liss, 1989: 43–67

    Google Scholar 

  6. Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1286–92

    Article  PubMed  CAS  Google Scholar 

  7. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470–8

    Article  PubMed  CAS  Google Scholar 

  8. Beisswenger PJ, Moore LL, Brinck-Johnsen T, et al. Increased collagen-linked pentosidine levels and advanced glycosylation end-products in early diabetic nephropathy. J Clin Invest 1993; 92: 2212–7

    Article  Google Scholar 

  9. Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation and crosslinking of collagen by glucose: kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676–83

    Article  PubMed  CAS  Google Scholar 

  10. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sei U S A 1994; 91: 9441–5

    Article  CAS  Google Scholar 

  11. Fu MX, Requena JR, Jenkins AJ, et al. The advanced glycation end-product, Nε-(carboxymethyl)-lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982–6

    Article  PubMed  CAS  Google Scholar 

  12. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654–67

    PubMed  CAS  Google Scholar 

  13. Baynes JW. The role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40: 405–12

    Article  PubMed  CAS  Google Scholar 

  14. Baynes JW. Role of oxidation chemistry in the Maillard reaction in vivo. In: Ikan R, editor. The Maillard reaction in biological systems. New York: John Wiley, 1995

    Google Scholar 

  15. Baynes JW. Reactive oxygen in the aetiology and complications of diabetes. In: Ioannides C, editor. Drugs, diet and disease. Vol. 2: Mechanistic approaches to diabetes. London: Pergamon Press, 1996

    Google Scholar 

  16. Thornalley PJ. The glyoxalase system: new developments toward functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269: 1–11

    PubMed  CAS  Google Scholar 

  17. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463–9

    Article  PubMed  CAS  Google Scholar 

  18. Al-Abed Y, Liebich H, Voelter W, et al. Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chem 1996; 271: 2892–6

    Article  PubMed  CAS  Google Scholar 

  19. Lyons TJ, Li W, Wells-Knecht MC, et al. Toxicity of mildly modified low density lipoprotein to cultured retinal capillary cells and pericytes. Diabetes 1994; 43: 1090–5

    Article  PubMed  CAS  Google Scholar 

  20. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Nat Acad Sci U S A 1993; 90: 6436–8

    Google Scholar 

  21. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110–7

    Article  PubMed  CAS  Google Scholar 

  22. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785–92

    Article  PubMed  CAS  Google Scholar 

  23. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, et al. Nε-(carboxymethyl)lysine is a dominant advanced glycation end-product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872–8

    Article  PubMed  CAS  Google Scholar 

  24. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE, a circulating marker of advanced glycosylation. Science 1992; 258: 651–3

    Article  PubMed  CAS  Google Scholar 

  25. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836–42

    Article  PubMed  CAS  Google Scholar 

  26. Papanastasiou P, Grass L, Rodela H, et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46: 216–22

    Article  PubMed  CAS  Google Scholar 

  27. Odetti P, Fogarty J, Sell DR, et al. Chromatographie quantitation of plasma and red cell pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153–9

    Article  PubMed  CAS  Google Scholar 

  28. Hricik DE, Schulak JA, Sell DR, et al. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993; 43: 398–403

    Article  PubMed  CAS  Google Scholar 

  29. Miyata T, Oda O, Inagi R, et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243–52

    Article  PubMed  CAS  Google Scholar 

  30. Miyata T, Inagi R, Iida Y, et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521–8

    Article  PubMed  CAS  Google Scholar 

  31. Smith MA, Taneda A, Richey PL, et al. Advanced Maillard reaction endproducts are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994; 91: 5170–4

    Google Scholar 

  32. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sei U S A 1994; 91: 7787–91

    Article  CAS  Google Scholar 

  33. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91: 4766–70

    Article  PubMed  CAS  Google Scholar 

  34. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889–97

    PubMed  CAS  Google Scholar 

  35. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521–8

    Article  PubMed  CAS  Google Scholar 

  36. Wautier JL, Wautier MP, Schmidt AM et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994; 91: 7742–6

    Article  PubMed  CAS  Google Scholar 

  37. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432–8

    Article  PubMed  CAS  Google Scholar 

  38. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: what role for oxidative stress? Metabolism 1995; 44: 363–8

    Article  PubMed  CAS  Google Scholar 

  39. Taneda S, Monnier VM. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 1994; 40: 1766–73

    PubMed  CAS  Google Scholar 

  40. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629–32

    Article  PubMed  CAS  Google Scholar 

  41. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular function by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221–32

    Article  PubMed  CAS  Google Scholar 

  42. Picard S, Parthasarathy S, Fruebis J, et al. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc Natl Acad Sci U S A 1992; 89: 6876–80

    Article  PubMed  CAS  Google Scholar 

  43. Paolisso G, Scheen A, Lefebvre P. Glucose handling, diabetes and aging. Horm Res 1995; 43: 52–7

    Article  PubMed  CAS  Google Scholar 

  44. Yue DK, McLennan S, Handelsman DJ, et al. The effect of salicylates on nonenzymatic glycosylation and thermal stability of collagen in diabetic mice. Diabetes 1984; 33: 745–51

    Article  PubMed  CAS  Google Scholar 

  45. Yue DK, McLennan S, Handelsman DJ, et al. The effects of cyclooxygenase and lipoxygenase inhibitors on the collagen abnormalities in diabetic rats. Diabetes 1985; 34: 74–8

    Article  PubMed  CAS  Google Scholar 

  46. Yue TL, McKenna PJ, Gu JL, et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922–8

    Article  PubMed  CAS  Google Scholar 

  47. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry and School of Medicine, University of South Carolina, Columbia, South Carolina, USA

    Suzanne R. Thorpe &  John W. Baynes

Authors
  1. Suzanne R. Thorpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Baynes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. Baynes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thorpe, S.R., Baynes, J.W. Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging. Drugs & Aging 9, 69–77 (1996). https://doi.org/10.2165/00002512-199609020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609020-00001

Keywords

Search

Navigation